Spots Global Cancer Trial Database for karyopharm
Every month we try and update this database with for karyopharm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | NCT04768881 | Locally Advance... | Selinexor Pembrolizumab | 18 Years - | Karyopharm Therapeutics Inc | |
| SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | NCT02146833 | Prostate Cancer | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | NCT02628704 | Multiple Myelom... | Selinexor Placebo (for se... carfilzomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | NCT02431351 | Myelodysplastic... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | NCT02628704 | Multiple Myelom... | Selinexor Placebo (for se... carfilzomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor Treatment of Refractory Myeloma | NCT02336815 | Multiple Myelom... | Selinexor Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT02227251 | Diffuse Large B... | Selinexor Selinexor Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | NCT02025985 | Ovarian Carcino... Endometrial Car... Cervical Carcin... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | NCT02314247 | Peripheral T-ce... Cutaneous T-cel... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | NCT02702492 | Solid Tumors NHL | KPT-9274 Niacin ER Nivolumab | 18 Years - | Karyopharm Therapeutics Inc | |
| Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | NCT01986348 | Glioblastoma Glioma | Selinexor | 18 Years - | Karyopharm Therapeutics Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
